Mark S. Kleven

TL;DR: Compounds possessing “balanced” 5- HT1A receptor agonism and D2 antagonism and, in some cases, combined with other beneficial properties, such as 5-HT2A receptor antagonism, are efficacious in a broad range of rodent pharmacological models yet have a lower propensity to elicit EPS or metabolic dysfunction.

TL;DR: The results further characterize the involvement of DA receptors in the mediation of spontaneous eye blinks, reveal differential effects of direct and indirect agonists and suggest new directions for research into the neuroanatomical basis of DA-mediated spontaneous eye blinking.

TL;DR: The findings indicate that the balance of activity at 5-HT(1A) and D(2) receptors profoundly influences the activity of antipsychotics in this model of social withdrawal, and their potential benefit on at least some of the negative symptoms of schizophrenia.

TL;DR: The results indicated that, after a single oral administration, these compounds inhibited immobility in the FST more potently and more extensively than the clinically used antidepressant imipramine.

TL;DR: It is confirmed that 5-HT1A receptor activation reduces or even completely prevents the cataleptogenic potential of novel antipsychotic agents and indicates that the balance of affinity and/or efficacy between D2 and 5- HT1A receptors profoundly influences their pharmacological activities, and will likely impact their therapeutic profiles.